+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Axial Spondyloarthritis Market by Product Class (Conventional DMARDs, IL-17 Inhibitors, JAK Inhibitors), Treatment Line (First Line, Second Line, Third Line), Distribution Channel, Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Axial Spondyloarthritis Market by Product Class (Conventional DMARDs, IL-17 Inhibitors, JAK Inhibitors), Treatment Line (First Line, Second Line, Third Line), Distribution Channel, Route Of Administration, End User - Global Forecast 2025-2030- Product Image
Sale

Axial Spondyloarthritis Market by Product Class (Conventional DMARDs, IL-17 Inhibitors, JAK Inhibitors), Treatment Line (First Line, Second Line, Third Line), Distribution Channel, Route Of Administration, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924702
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The axial spondyloarthritis market is entering a period of strategic transformation, driven by medical innovation, evolving care models, and adaptive responses to shifting regulatory and economic environments. Senior decision-makers are increasingly challenged to align commercial, clinical, and operational strategies for sustainable advantage in this dynamic landscape.

Market Snapshot: Axial Spondyloarthritis Market Growth and Dynamics

The Axial Spondyloarthritis Market grew from USD 5.68 billion in 2024 to USD 6.12 billion in 2025. It is expected to continue growing at a CAGR of 7.54%, reaching USD 8.79 billion by 2030. This upward momentum reflects increasing therapeutic adoption, advances in diagnostics, and regional shifts in healthcare infrastructure. Companies are actively developing new solutions to address gaps in patient care and optimize engagement across the continuum of management.

Scope & Segmentation

This research delivers a comprehensive overview of the axial spondyloarthritis market, analyzing products, treatment lines, distribution, administration, end users, and regions:

  • Product Classes: Conventional DMARDs (Hydroxychloroquine, Methotrexate, Sulfasalazine), IL-17 inhibitors (Brodalumab, Ixekizumab, Secukinumab), JAK inhibitors (Filgotinib, Tofacitinib, Upadacitinib), NSAIDs (Diclofenac, Ibuprofen, Naproxen), TNF inhibitors (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab)
  • Treatment Lines: First Line, Second Line, Third Line
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • Routes of Administration: Injectable, Intravenous, Oral
  • End Users: Home Care, Hospitals, Specialty Clinics
  • Geographic Coverage: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Companies Covered: AbbVie Inc., Novartis AG, Janssen Biotech, Inc., Eli Lilly and Company, UCB S.A., Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Merck & Co., Inc.

Key Takeaways: Strategic Insights for Leadership

  • Therapeutic innovation is transforming the management of axial spondyloarthritis, with next-generation biologics and small molecules expanding clinical options and reinforcing the need for flexible treatment strategies.
  • Digital health platforms are enabling earlier diagnosis and better disease monitoring, supporting patient engagement and provider decision-making across varied care settings.
  • Regional adoption differs considerably: advanced economies prioritize rapid uptake of novel therapeutics and early intervention, while emerging markets invest in biosimilars and local manufacturing to broaden access.
  • Complex supply chain dynamics and regulatory changes require companies to localize production, optimize sourcing, and strengthen relationships with distributors and hospital pharmacies.
  • Segmentation by therapy line, route, and care setting highlights significant diversity in prescriber preferences and patient pathways, underscoring the advantage of tailored engagement models.
  • Strategic alliances, acquisitions, and technology partnerships are driving product pipeline diversification and enhancing competitive positioning globally.

Tariff Impact: Navigating Regulatory and Supply Chain Adjustments

The 2025 US tariff revisions introduced new cost pressures for manufacturers of axial spondyloarthritis therapies, particularly in biologic sourcing and specialty chemical components. Companies have swiftly adapted, scaling local production, reshaping procurement strategies, and renegotiating supply contracts to ensure consistent patient access and maintain competitive pricing structures.

Methodology & Data Sources

This report uses a rigorous, multi-phase approach: secondary research analyzing literature, regulatory and clinical sources; primary KOL, clinician, payer, and supply-chain interviews; and a robust analytical framework combining quantitative and qualitative techniques. Independent advisory review by experts ensures all conclusions and recommendations are market-grounded and actionable.

Why This Report Matters

  • Enables strategic planning by elucidating emerging market drivers, key innovation areas, and regional challenges, scalable for executive and operational teams.
  • Guides product, partnership, and geographic investment by integrating segmentation, patient pathway analysis, and supply chain considerations.
  • Supports risk mitigation and opportunity capture by revealing critical regulatory trends, supply chain adaptations, and technology-driven care advances.

Conclusion

Staying ahead in the axial spondyloarthritis market requires synchronized strategies across innovation, commercialization, and care delivery. This report arms leaders with the insights needed to navigate evolving challenges and seize emerging opportunities in this fast-changing therapeutic field.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of JAK inhibitors for nonradiographic axial spondyloarthritis patients unresponsive to first-line TNF blockers
5.2. Increasing investment in biomarker-driven diagnostics enabling early detection of axial spondyloarthritis progression
5.3. Expansion of telemedicine platforms integrating patient-reported outcomes for remote monitoring of disease activity
5.4. Emergence of bispecific antibody candidates targeting both TNF and IL-17 pathways in pipeline trials
5.5. Growing competition from biosimilar etanercept and adalimumab affecting pricing and market access strategies
5.6. Implementation of quantitative MRI scoring algorithms to improve early diagnosis and treatment stratification
5.7. Adoption of value-based contracting models with payers emphasizing long-term functional outcomes in axial spondyloarthritis biologics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Axial Spondyloarthritis Market, by Product Class
8.1. Introduction
8.2. Conventional DMARDs
8.2.1. Hydroxychloroquine
8.2.2. Methotrexate
8.2.3. Sulfasalazine
8.3. IL-17 Inhibitors
8.3.1. Brodalumab
8.3.2. Ixekizumab
8.3.3. Secukinumab
8.4. JAK Inhibitors
8.4.1. Filgotinib
8.4.2. Tofacitinib
8.4.3. Upadacitinib
8.5. NSAIDs
8.5.1. Diclofenac
8.5.2. Ibuprofen
8.5.3. Naproxen
8.6. TNF Inhibitors
8.6.1. Adalimumab
8.6.2. Certolizumab
8.6.3. Etanercept
8.6.4. Golimumab
8.6.5. Infliximab
9. Axial Spondyloarthritis Market, by Treatment Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line
10. Axial Spondyloarthritis Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Axial Spondyloarthritis Market, by Route Of Administration
11.1. Introduction
11.2. Injectable
11.3. Intravenous
11.4. Oral
12. Axial Spondyloarthritis Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Axial Spondyloarthritis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Axial Spondyloarthritis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Axial Spondyloarthritis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Novartis AG
16.3.3. Janssen Biotech, Inc.
16.3.4. Eli Lilly and Company
16.3.5. UCB S.A.
16.3.6. Amgen Inc.
16.3.7. Pfizer Inc.
16.3.8. Bristol-Myers Squibb Company
16.3.9. Merck & Co., Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. AXIAL SPONDYLOARTHRITIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. AXIAL SPONDYLOARTHRITIS MARKET: RESEARCHAI
FIGURE 26. AXIAL SPONDYLOARTHRITIS MARKET: RESEARCHSTATISTICS
FIGURE 27. AXIAL SPONDYLOARTHRITIS MARKET: RESEARCHCONTACTS
FIGURE 28. AXIAL SPONDYLOARTHRITIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. AXIAL SPONDYLOARTHRITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FILGOTINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TOFACITINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY UPADACITINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ETANERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GOLIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 141. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 142. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 143. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 144. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 145. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 146. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 147. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 148. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 149. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 150. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 151. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 152. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 153. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 154. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 155. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 174. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 175. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 264. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 265. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 272. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 273. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 276. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 277. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 284. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 285. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 286. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 287. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 288. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 289. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 290. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 291. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 292. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 293. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 294. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 295. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 296. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 297. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY PRODUCT CLASS, 2025-2030 (USD MILLION)
TABLE 305. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2024 (USD MILLION)
TABLE 306. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CONVENTIONAL DMARDS, 2025-2030 (USD MILLION)
TABLE 307. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 308. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY IL-17 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 309. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 310. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 311. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 312. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 313. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 314. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 315. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 316. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 317. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 320. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Axial Spondyloarthritis market report include:
  • AbbVie Inc.
  • Novartis AG
  • Janssen Biotech, Inc.
  • Eli Lilly and Company
  • UCB S.A.
  • Amgen Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.12 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.79 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Medications for Non-Radiographic Axial Spondyloarthritis Market by Mechanism Of Action (IL-17 Inhibitors, JAK Inhibitors, TNF Inhibitors), Drug Class (Biologics, Small Molecules), Line Of Therapy, Route Of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Medications for Non-Radiographic Axial Spondyloarthritis Market by Mechanism Of Action (IL-17 Inhibitors, JAK Inhibitors, TNF Inhibitors), Drug Class (Biologics, Small Molecules), Line Of Therapy, Route Of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Non-Radiographic Axial Spondyloarthritis Therapeutic Global Market Report 2025 - Product Image

Non-Radiographic Axial Spondyloarthritis Therapeutic Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Axial Spondyloarthritis (AxSpA) Market Report 2025 - Product Image

Axial Spondyloarthritis (AxSpA) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Axial Spondyloarthritis (axSpA) - Pipeline Insight, 2025 - Product Image

Axial Spondyloarthritis (axSpA) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Axial Spondyloarthritis (AXSPA) - Global Strategic Business Report - Product Image

Axial Spondyloarthritis (AXSPA) - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From

About the Axial Spondyloarthritis Drug Market

Axial Spondyloarthritis (axSpA) is a type of inflammatory arthritis that affects the spine and sacroiliac joints. It is a chronic, progressive condition that can cause pain, stiffness, and swelling in the affected areas. Immune Disorders Drugs are used to treat axSpA, as they help to reduce inflammation and pain. These drugs can be taken orally, injected, or infused, depending on the severity of the condition. Commonly used drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and corticosteroids. The Axial Spondyloarthritis Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of axSpA, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.